These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 35430474)
1. Molecular modelling identification of phytocompounds from selected African botanicals as promising therapeutics against druggable human host cell targets of SARS-CoV-2. Uhomoibhi JO; Shode FO; Idowu KA; Sabiu S J Mol Graph Model; 2022 Jul; 114():108185. PubMed ID: 35430474 [TBL] [Abstract][Full Text] [Related]
2. Molecular docking analysis reveals the functional inhibitory effect of Genistein and Quercetin on TMPRSS2: SARS-COV-2 cell entry facilitator spike protein. Manjunathan R; Periyaswami V; Mitra K; Rosita AS; Pandya M; Selvaraj J; Ravi L; Devarajan N; Doble M BMC Bioinformatics; 2022 May; 23(1):180. PubMed ID: 35578172 [TBL] [Abstract][Full Text] [Related]
3. Computational exploration of the dual role of the phytochemical fortunellin: Antiviral activities against SARS-CoV-2 and immunomodulatory abilities against the host. Agrawal S; Pathak E; Mishra R; Mishra V; Parveen A; Mishra SK; Byadgi PS; Dubey SK; Chaudhary AK; Singh V; Chaurasia RN; Atri N Comput Biol Med; 2022 Oct; 149():106049. PubMed ID: 36103744 [TBL] [Abstract][Full Text] [Related]
4. Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease. Fadaka AO; Sibuyi NRS; Martin DR; Klein A; Madiehe A; Meyer M Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502340 [TBL] [Abstract][Full Text] [Related]
5. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2. Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390 [TBL] [Abstract][Full Text] [Related]
9. Biflavonoids from Lokhande K; Nawani N; K Venkateswara S; Pawar S J Biomol Struct Dyn; 2022 Jul; 40(10):4376-4388. PubMed ID: 33300454 [TBL] [Abstract][Full Text] [Related]
10. Exploring the Therapeutic Potential of Ali MA; Sheikh H; Yaseen M; Faruqe MO; Ullah I; Kumar N; Bhat MA; Mollah MNH Molecules; 2024 May; 29(11):. PubMed ID: 38893400 [TBL] [Abstract][Full Text] [Related]
11. Computational profiling of natural compounds as promising inhibitors against the spike proteins of SARS-CoV-2 wild-type and the variants of concern, viral cell-entry process, and cytokine storm in COVID-19. Kar P; Saleh-E-In MM; Jaishee N; Anandraj A; Kormuth E; Vellingiri B; Angione C; Rahman PKSM; Pillay S; Sen A; Naidoo D; Roy A; Choi YE J Cell Biochem; 2022 May; 123(5):964-986. PubMed ID: 35342986 [TBL] [Abstract][Full Text] [Related]
12. Anisotine and amarogentin as promising inhibitory candidates against SARS-CoV-2 proteins: a computational investigation. Kar P; Kumar V; Vellingiri B; Sen A; Jaishee N; Anandraj A; Malhotra H; Bhattacharyya S; Mukhopadhyay S; Kinoshita M; Govindasamy V; Roy A; Naidoo D; Subramaniam MD J Biomol Struct Dyn; 2022 Jul; 40(10):4532-4542. PubMed ID: 33305988 [TBL] [Abstract][Full Text] [Related]
13. Natural phyto, compounds as possible noncovalent inhibitors against SARS-CoV2 protease: computational approach. Ogidigo JO; Iwuchukwu EA; Ibeji CU; Okpalefe O; Soliman MES J Biomol Struct Dyn; 2022 Mar; 40(5):2284-2301. PubMed ID: 33103616 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory mechanism of clioquinol and its derivatives at the exopeptidase site of human angiotensin-converting enzyme-2 and receptor binding domain of SARS-CoV-2 viral spike. Kehinde IA; Egbeyemi A; Kaur M; Onyenaka C; Adebusuyi T; Olaleye OA J Biomol Struct Dyn; 2023 Apr; 41(7):2992-3001. PubMed ID: 35220925 [TBL] [Abstract][Full Text] [Related]
15. Identification of Kaempferol as Viral Entry Inhibitor and DL-Arginine as Viral Replication Inhibitor from Selected Plants of Indian Traditional Medicine against COVID-19: An Jayaprakashkamath A; Murali M; Nair B; Benny F; Mani RP; Suresh D; Presanna AT; Areekkara AN; Nath LR Curr Comput Aided Drug Des; 2023; 19(4):313-323. PubMed ID: 36635906 [TBL] [Abstract][Full Text] [Related]
16. In Silico Identification of Potential Natural Product Inhibitors of Human Proteases Key to SARS-CoV-2 Infection. Vivek-Ananth RP; Rana A; Rajan N; Biswal HS; Samal A Molecules; 2020 Aug; 25(17):. PubMed ID: 32842606 [TBL] [Abstract][Full Text] [Related]
17. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses. Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205 [TBL] [Abstract][Full Text] [Related]
18. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach. Mishra CB; Pandey P; Sharma RD; Malik MZ; Mongre RK; Lynn AM; Prasad R; Jeon R; Prakash A Brief Bioinform; 2021 Mar; 22(2):1346-1360. PubMed ID: 33386025 [TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M Ghosh A; Chakraborty M; Chandra A; Alam MP J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023 [TBL] [Abstract][Full Text] [Related]
20. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]